An International Phase 3 Randomized Trial of Autologus Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)
|Effective start/end date
|11/1/12 → 11/30/18
- ARGOS THERAPEUTICS, INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.